Related Experiment Video

Updated: Jan 4, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

14.1K

[Clinical Effect of Nivolumab on Advanced Renal Cell Carcinoma with Peritoneal Metastasis]

Takuya Hida1, Toshinari Yamasaki1, Haruka Banno1

  • 1The Department of Urology, Kyoto University Hospital.

Hinyokika Kiyo. Acta Urologica Japonica
|November 8, 2019
PubMed

Insights

This study reports on four advanced renal cell carcinoma patients with peritoneal metastases treated with nivolumab. Three patients showed objective responses, suggesting nivolumab

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Peritoneal metastasis from renal cell carcinoma (RCC) is rare.
  • Advanced RCC with peritoneal spread presents a therapeutic challenge.

Purpose of the Study:

  • To evaluate the efficacy of nivolumab in patients with advanced renal cell carcinoma and peritoneal metastases.
  • To identify potential biomarkers for treatment response.

Main Methods:

  • Case series of four patients with advanced RCC and peritoneal metastases.
  • Treatment with nivolumab.
  • Monitoring of metastatic lesions via computed tomography (CT) scans.
  • Assessment of temporal changes in neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), and eosinophil ratio.

Main Results:

  • Three out of four patients achieved an objective response in peritoneal metastatic lesions.
  • Transient enlargement of peritoneal lesions (pseudoprogression) was observed in two patients post-nivolumab initiation.
  • Changes in NLR, CRP, and eosinophil ratio correlated with treatment response.

Conclusions:

  • Nivolumab demonstrates therapeutic activity against peritoneal metastases in advanced renal cell carcinoma.
  • Nivolumab may be a viable treatment option for this rare presentation of RCC.
  • NLR, CRP, and eosinophil ratio show potential as predictive biomarkers for nivolumab response in RCC.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.1K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
502
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K